
TH Global Capital宣布推出成長顧問業務「TH Growth Strategy + Deal」,協助客戶持續創造價值
倫敦--(BUSINESS WIRE)--(美國商業資訊)-- TH Global Capital 是一家屢獲殊榮的全球投資銀行公司,連續三年被評為「年度最佳精品投資銀行公司」,業務遍及29個國家並成功完成多項交易。該公司欣然宣布推出「TH Growth Strategy + Deal」業務。這一強化版成長顧問業務旨在透過親力親為、以結果為導向的方式,協助全球中端市場企業釋放變革性成長潛力,推動策略性收入擴張,並執行高影響力交易。
該成長顧問業務使客戶能夠以更高估值退出、募集資金或進行資本重整。TH Global Capital與客戶密切合作,透過客製化介入措施提升業務水準,這些措施旨在推動收入的可衡量改善、加快訂單預訂、擴大業務版圖、提高息稅折舊攤銷前利潤率,並建構永續的銷售能力引擎,以達成釋放長期價值的目標。
TH Global Capital 創辦人 兼 執行長Vivek Subramanyam 表示:「儘快我們的許多客戶透過收購和募集成長資本實現了外延式成長,但我們越來越多地聽到他們希望推動內生成長並從內部釋放更深層價值的願望。TH Growth Strategy + Deal的推出強化了我們的承諾——不僅為交易提供顧問服務,還透過變革性成長和利潤率提升策略為客戶創造長期價值。透過與董事會和高階主管層密切合作,該策略旨在解決最受關注的挑戰,同時為交易提供顧問服務。」
這一措施進一步鞏固了TH Global Capital長期策略成長合作夥伴的地位,協助企業辨識和執行高影響力機會,並彌合策略與執行之間的差距,以推動可擴展和永續的成長。
獨特的價值主張:
憑藉在投資銀行和成長顧問領域數十年的經驗,TH Global Capital擁有為客戶推動可擴展成長的良好記錄。該公司憑藉在29個國家的多次業務合作中獲得的洞見,提供無與倫比的市場情報和策略背景。TH Global Capital不僅僅是顧問,更與客戶並肩合作,從營收成長、利潤率提升到估值提升,執行親力親為的策略以交付可衡量的成果。
如欲進一步瞭解TH Growth Strategy + Deal如何加快您的成長之旅,請造訪網站: https://thglobalcapital.com/services/growth-advisory/ 或透過 THGrowthStrategy_Deal@thglobalcapital.com 聯絡公司團隊。
免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
7 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.


Business Wire
2 days ago
- Business Wire
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68 th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.


Business Wire
2 days ago
- Business Wire
KBRA Releases Research – Potential OBBBA Implications for Litigation Finance ABS
NEW YORK--(BUSINESS WIRE)--KBRA releases research examining the potential implications for litigation finance ABS stemming from proposed measures under the Tackling Predatory Litigation Funding Act (TPLFA), which is currently included in the U.S. Senate's One Big Beautiful Bill Act (OBBBA). Litigation finance has a long history and, in recent years, has established itself as a niche segment in the asset-backed securities (ABS) market. However, the TPLFA could significantly alter the economics of this evolving structured finance asset class, as it proposes substantial new taxes on profits from third-party litigation funding. Litigation finance ABS transactions, which are typically backed by nonrecourse advances to plaintiffs in personal injury and other civil cases, could face meaningful structural and liquidity challenges if the legislation is enacted. Click here to view the report. Related Publication Litigation Finance ABS: Not Settling for Less About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010181